The publisher explores Boehringer Ingelheim’s prescription pharmaceutical performance and outlook over 2019–29.
Snapshot
Model updates (20 May 2020)
Model updates (6 August 2019)
Snapshot
- Overview: Boehringer Ingelheim will see near-term growth, but will see long-term revenue declines because of fewer NMEs in its late-stage pipeline compared to its peers.
- Key themes: [1] Upcoming label expansions for Jardiance should help to sustain recent robust revenue trends [2] Ofev should see continued growth in idiopathic pulmonary fibrosis (IPF) and interstitial lung disease associated with systemic sclerosis (SSc-ILD) [3] Boehringer Ingelheim will see royalties from Skyrizi, which has already become a blockbuster product for AbbVie.
Model updates (20 May 2020)
- Jardiance forecast adjusted higher
- Glyxambi forecast removed due to Boehringer not providing brand-level revenue performance
- Stiolto forecast removed due to Boehringer not providing brand-level revenue performance.
Model updates (6 August 2019)
- Ofev forecast adjusted higher due to market share gains within IPF
- Jardiance forecast adjusted higher due to strong growth.
Table of Contents
Company Background- Company Overview
- SWOT Analysis
- Key Drug & Company Information
- Company Comparison
Company Forecast
- Prescription Pharmaceuticals Sales Outlook
- Branded Drug Outlook
- Therapy Area Outlook
- Regional Sales Outlook
- Lifecycle Analysis
Company Profile
- Marketed & Pipeline Drugs
- Recent Events & Analyst Opinions
- Upcoming Catalysts
- Recent Insights
Clinical Trial Overview
- Clinical Trial Snapshot
- Clinical Trials by Country
- Clinical Trials by Status and Phase
- Clinical Trials by Drug
